Gilead Sciences Inc. (NASDAQ:GILD) – European CHMP Adopts Positive Opinion for Gilead Sciences’ Sovaldi® for the Treatment of Chronic Hepatitis C Infection

[Business Wire] – Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has adopted a positive opinion on . . . → Read More: Gilead Sciences Inc. (NASDAQ:GILD) – European CHMP Adopts Positive Opinion for Gilead Sciences’ Sovaldi® for the Treatment of Chronic Hepatitis C Infection Similar posts: AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review Data from Merck’s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting – Merck & Co. Inc. (NYSE:MRK)